Walleye Capital
ZNTL icon

Walleye Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Walleye Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110,448
Closed -$149K – 5089
2025
Q4 		$149K Sell
110,448
-10,000
-8% -$14.6K ﹤0.01% 3686
2025
Q3 		$182K Sell
120,448
-9,419
-7% -$14.1K ﹤0.01% 3374
2025
Q2 		$151K Sell
129,867
-211,521
-62% -$279K ﹤0.01% 3554
2025
Q1 		$543K Buy
341,388
+147,679
+76% +$318K ﹤0.01% 2490
2024
Q4 		$587K Buy
+193,709
New +$635K ﹤0.01% 2861
2024
Q3 		– Sell
-22,021
Closed -$90.1K – 5954
2024
Q2 		$90.1K Buy
+22,021
New +$246K ﹤0.01% 4766
2022
Q4 		– Sell
-85,529
Closed -$1.85M – 3701
2022
Q3 		$1.85M Buy
+85,529
New +$2.34M 0.04% 609
2022
Q2 		– Sell
-20,455
Closed -$944K – 2760
2022
Q1 		$944K Buy
20,455
+7,117
+53% +$384K 0.03% 667
2021
Q4 		$1.12M Buy
+13,338
New +$1.03M 0.03% 520

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Walleye Capital's ZNTL Position: Q1 2026 in Review

Walleye Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 110,448 shares — an estimated $149K sold.

Walleye Capital first reported a position in ZNTL in Q4 2021 and held it in 9 quarters. The position peaked at $1.85M in Q3 2022. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Walleye Capital reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 110,448 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $149K.
  • Walleye Capital first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Walleye Capital's Zentalis Pharmaceuticals position peaked at $1.85M in Q3 2022.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.